Physician profile
Angela M Velez
NPI 1558558809
$6,962.35
in general payments reported to CMS, 2019-2025
31 companies · $906 in 2025
The $906 reported for 2025 was more than what a typical Clinical Neurophysiology provider received nationally (typical 2025 total: $435).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $885 · 2020: $227 · 2021: $1,069 · 2022: $1,256 · 2023: $969 · 2024: $1,650 · 2025: $906.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,525.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,525.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,142.49 | 2021-2025 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $742.82 | 2019-2025 | Rexulti, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $724.17 | 2021-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $702.85 | 2019-2025 | Trintellix |
| Sunovion Pharmaceuticals INC. | $436.83 | 2020-2022 | |
| Alkermes, INC. | $402.45 | 2022-2025 | Aristada, Lybalvi |
| Lundbeck LLC | $386.98 | 2019-2025 | Rexulti |
| Almatica Pharma LLC | $366.05 | 2022-2025 | Loreev Xr, Sertraline Hcl |
| Ironshore Pharmaceuticals INC. | $299.36 | 2019-2023 | Jornay Pm |
| Tris Pharma INC | $247.32 | 2023-2024 | Dyanavel Xr |
| Vanda Pharmaceuticals INC. | $229.17 | 2019-2025 | Fanapt, Hetlioz |
| Corium, LLC | $220.93 | 2022-2024 | Azstarys |
| Janssen Pharmaceuticals, INC | $182.59 | 2019-2025 | Spravato, Invega Sustenna |
| Allergan, INC. | $165.83 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $95.78 | 2021-2025 | Qelbree |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $86.79 | 2019-2022 | |
| Collegium Pharmaceutical, INC. | $69.29 | 2025 | Jornay Pm |
| Biogen, INC. | $63.68 | 2024 | |
| Idorsia Pharmaceuticals US INC | $58.31 | 2023 | Quviviq |
| Teva Pharmaceuticals USA, INC. | $52.51 | 2019-2021 | |
| Bausch Health US, LLC | $46.65 | 2019-2021 | |
| Adlon Therapeutics L.P. | $40.49 | 2019-2021 | |
| Neos Therapeutics, Lp | $37.82 | 2021-2022 | |
| Neuronetics, INC. | $30.83 | 2019-2023 | Neurostar Tms Therapy System |
| Jazz Pharmaceuticals INC. | $24.17 | 2019 | |
| Brainsway USA INC | $20.51 | 2022 | |
| Neurocrine Biosciences, INC. | $19.84 | 2022 | |
| Axsome Therapeutics, INC. | $19.16 | 2025 | Auvelity |
| Eisai INC. | $17.54 | 2021 | |
| Shire North American Group INC | $15.56 | 2019 | |
| Noven Therapeutics, LLC | $13.58 | 2023 | Xelstrym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angela Velez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.